Upgrade to SI Premium - Free Trial

RBC Capital Reiterates Outperform Rating on Abbvie (ABBV)

July 1, 2026 8:01 AM
RBC Capital analyst Trung Huynh reiterated an Outperform rating and $260.00 price target on Abbvie (NYSE: ABBV).The analyst commented: "Immunology ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments